Watch Our Story in Action
In one of our original videos, our founder, Dr. Geoff Hoffmann, describes early findings and how AbstimX modulates the immune system.
In this compelling interview, Dr. Reginald Gorczynski shares breakthrough insights on rebalancing immunity using naturally occurring antibodies, with potential applications across a range of inflammatory diseases.
Learn about Network Immunology and how our technology works to reduce allergies and improve autoimmune diseases.
Latest Updates
Canine Clinical Trial Underway
Network Immunology has initiated a canine clinical trial evaluating AbstimX™, its first-in-class immune-modulating therapy designed to restore immune balance without suppressing immune function.
Dogs naturally develop allergic and inflammatory diseases that closely mirror human conditions, making this study a key step in validating AbstimX™’s mechanism in a clinically relevant model. The trial will assess safety, immune response, and early efficacy signals in dogs with chronic allergic disease, generating translational data to inform future human development.
This milestone advances Network Immunology’s human-first strategy by leveraging high-quality canine clinical data to de-risk and accelerate programs targeting chronic inflammatory and autoimmune diseases.